Preclinical evaluation of a ricinoleic acid poloxamer gel system for transdermal eyelid delivery

Abstract Our previous study has shown that pluronic lecithin organogel (PLO gel) made of ricinoleic acid has the potential for use as a transdermal eyelid delivery system. The present study deals with the evaluation of ocular tissue concentrations of dexamethasone in a rabbit model following topical application of the gel formulation onto the eyelids. The PLO gel formulation containing dexamethasone was applied to the outside of the eyelid skin. Rabbits were sacrificed at regular time intervals of 2, 4, 8, 12, 20 and 24 h. Maxidex ® eye drops were used as a control. Rabbits were sacrificed and dexamethasone concentrations were analyzed in anterior segment tissues such as the cornea, conjunctiva, aqueous humor, lens, and iris-ciliary body by liquid chromatography tandem mass spectrometry (LC–MS/MS). Rabbit eyes were also examined for ocular irritation and scored using the modified Draize scoring system. No significant irritation or redness was observed in the eyes as compared to the control rabbit eyes. PLO gel formulation resulted in constant dexamethasone concentrations in the anterior segment tissues for up to 24 h, which was equivalent or higher than Maxidex ® eye drops. The findings of this investigation indicate that the ricinoleic acid PLO gel formulation may be clinically effective as a new treatment modality for anterior segment diseases.